Al­ladapt gets $100M+ to see its all-in-one oral im­munother­a­py al­ler­gy drug through clin­i­cal tri­als

Most food al­ler­gy care in­volves avoid­ance — check­ing in­gre­di­ent la­bels, no peanut ta­bles in schools, and so on. How­ev­er, that par­a­digm has been shift­ing with oral im­munother­a­pies, or OITs for short, in which pa­tients pur­pose­ly eat a bit of their al­ler­gen in the form of a mod­i­fied pro­tein in hopes of train­ing their im­mune sys­tem to tol­er­ate it.

Al­ladapt Im­munother­a­peu­tics is cre­at­ing a sin­gle OIT for all ma­jor IgE-me­di­at­ed food al­ler­gies — “what we call the big nine,” as Al­ladapt CEO Ash­ley Dom­bkows­ki said — for milk, eggs, wheat, fish, shell­fish, peanuts, tree nuts, soy and sesame. Now, the biotech has $119 mil­lion to push that drug through clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER